Production of a conjugate vaccine for Salmonella enterica serovar Typhi from Citrobacter Vi.

F Micoli, S Rondini, I Pisoni, C Giannelli, V Di Cioccio, P Costantino, A Saul, L B Martin

Novartis Vaccines Institute for Global Health, Via Fiorentina 1, 53100 Siena, Italy. francesca.micoli@novartis.com

Vaccine 2012 Jan 20

filter terms:

A conjugate vaccine for Salmonella enterica serovar Typhi was produced by chemically linking Vi, purified from Citrobacter, to the non-toxic mutant diphtheria toxin CRM(197) via an adipic dihydrazide spacer using N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide coupling chemistry. The polysaccharide purification process was developed based on Vi precipitation from culture supernatant with cetyl trimethylammonium bromide (CTAB), solubilization of the CTA-polysaccharide salt with ethanol followed by exchange of the CTA(+) counter ion with Na(+). The purified Vi polysaccharide was fully O-acetylated and with high purity. The conjugation process was optimized to obtain a scalable process that has been used for GMP production at pilot scale of vaccine currently in clinical trials. Copyright © 2011 Elsevier Ltd. All rights reserved.

Citation

F Micoli, S Rondini, I Pisoni, C Giannelli, V Di Cioccio, P Costantino, A Saul, L B Martin. Production of a conjugate vaccine for Salmonella enterica serovar Typhi from Citrobacter Vi. Vaccine. 2012 Jan 20;30(5):853-61